Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Effectiveness and safety of ustekinumab intensification at 90 Mg every four weeks In Crohn's disease: a multicenter study

Mathurin Fumery 1, 2 Laurent Peyrin-Biroulet 3, 4 Stéphane Nancey 5, 6 Romain Altwegg 7 Cyrielle Gilletta 8 Pauline Veyrard 9 Guillaume Bouguen 10, 11, 12 Stephanie Viennot 8 Florian Poullenot 13 Jérôme Filippi 14 Anthony Buisson 15 Anne Bozon 16 Franck Brazier 1, 2 Lieven Pouillon 3 Bernard Flourie 5, 6 Lucile Boivineau 7 Laurent Siproudhis 10, 11, 12 David Laharie 17 Xavier Roblin 9 Momar Diouf 18 Xavier Tréton 16
Abstract : Introduction: The approved maintenance regimens for ustekinumab in Crohn's disease (CD) are 90 mg every 8 or 12 weeks. Some patients will partially respond to ustekinumab or will experience a secondary loss of response. It remains poorly known if these patients may benefit from shortening the interval between injections.Methods: All patients with active CD, as defined by Harvey-Bradshaw score ≥ 4 and one objective sign of inflammation (CRP > 5 mg/L and/or fecal calprotectin > 250 µg/g and/or radiologic and/or endoscopic evidence of disease activity) who required ustekinumab dose escalation to 90mg every 4 weeks for loss of response or incomplete response to ustekinumab 90mg every 8 weeks were included in this retrospective multicenter cohort study.Results: One hundred patients, with a median age of 35 years (Interquartile Range (IQR), 28 - 49) and median disease duration of 12 (7 - 20) years were included. Dose intensification was performed after a median of 5.0 (2.8 - 9.0) months of ustekinumab treatment and was associated with corticosteroids and immunosuppressants in respectively 29% and 27% of cases. Short-term clinical response and clinical remission were observed in respectively 61% and 31% after a median of 2.4 (1.3 - 3.0) months. After a median follow-up of 8.2 (5.6-12.4) months, 61% of patients were still treated with ustekinumab, and 26% in steroid-free clinical remission. Among the 39 patients with colonoscopy during follow-up, 14 achieved endoscopic remission (no ulcers). At the end of follow-up, 27% of patients were hospitalized, and 19% underwent intestinal resection surgery. Adverse events were reported in 12% of patients, including five serious adverse events.Conclusion: In this multicenter study, two-thirds of patients recaptured response following treatment intensification with ustekinumab 90 mg every 4 weeks.
Liste complète des métadonnées

Littérature citée [16 références]  Voir  Masquer  Télécharger
Contributeur : Laurent Jonchère <>
Soumis le : lundi 19 octobre 2020 - 15:44:29
Dernière modification le : jeudi 9 septembre 2021 - 11:32:53
Archivage à long terme le : : mercredi 20 janvier 2021 - 19:02:21


Fumery et al-2020-Effectivenes...
Fichiers produits par l'(les) auteur(s)



Mathurin Fumery, Laurent Peyrin-Biroulet, Stéphane Nancey, Romain Altwegg, Cyrielle Gilletta, et al.. Effectiveness and safety of ustekinumab intensification at 90 Mg every four weeks In Crohn's disease: a multicenter study. Journal of Crohn's and Colitis, Elsevier - Oxford University Press, 2021, 15 (2), pp.222-227. ⟨10.1093/ecco-jcc/jjaa177⟩. ⟨hal-02959922⟩



Consultations de la notice


Téléchargements de fichiers